4 free views remaining today

pigmented villonodular synovitis

ICD-10 Codes

Related ICD-10:

Description

Pigmented Villonodular Synovitis (PVNS): A Rare Joint Condition

Pigmented villonodular synovitis (PVNS) is a rare condition that affects the joints and tendons, causing them to thicken and overgrow. This leads to the formation of a non-cancerous tumor-like mass in the affected joint.

Characteristics:

  • PVNS is a benign (non-cancerous) condition that does not spread to other areas of the body.
  • It affects the synovium, which is the thin layer of tissue that lines the joints and tendons.
  • The condition can cause large tumors to form in the affected joint.
  • PVNS typically affects adults between 30 and 40 years old.

Types:

  • Localized PVNS: This type affects a single joint or tendon sheath.
  • Diffuse PVNS: This type affects multiple joints or tendon sheaths simultaneously.

Symptoms:

  • Painful swelling in the affected joint
  • Joint stiffness and limited mobility
  • Swelling and redness around the affected area

Causes:

  • The exact cause of PVNS is unknown, but it is thought to be related to a neoplastic process (abnormal cell growth).

Treatment:

  • Treatment for PVNS typically involves surgical removal of the affected tissue.
  • In some cases, medication may be prescribed to manage symptoms and prevent further joint damage.

References:

  • [1] Description. In a healthy joint, the synovium is a thin layer of tissue that lines the joints and tendons. (Source: #1)
  • [2] PVNS is typically categorized as localized or diffuse. It is also called tenosynovial giant cell tumor when it occurs in a tendon. (Source: #11)
  • [3] The lesion is composed of papillary, villous, and nodular areas covered by synovium. Some foci show large pseudoglandular or cleft-like spaces with a prominent cellular component. (Source: #13)

Additional Characteristics

  • Pigmented villonodular synovitis (PVNS) is a rare condition that affects the joints and tendons, causing them to thicken and overgrow.
  • It affects the synovium, which is the thin layer of tissue that lines the joints and tendons.
  • The condition can cause large tumors to form in the affected joint.
  • PVNS typically affects adults between 30 and 40 years old.
  • In a healthy joint, the synovium is a thin layer of tissue that lines the joints and tendons.
  • PVNS is typically categorized as localized or diffuse. It is also called tenosynovial giant cell tumor when it occurs in a tendon.
  • The lesion is composed of papillary, villous, and nodular areas covered by synovium. Some foci show large pseudoglandular or cleft-like spaces with a prominent cellular component.

Signs and Symptoms

Common Signs and Symptoms of Pigmented Villonodular Synovitis (PVNS)

Pigmented villonodular synovitis (PVNS) is a condition that can cause pain, swelling, and joint degeneration. The symptoms of PVNS can vary from person to person, but here are some common signs and symptoms:

  • Swelling: Swelling in the affected joint, which can be tender to the touch [9].
  • Pain: Pain in the affected joint, which can range from mild to severe [5][7].
  • Joint effusion: Fluid accumulation in the joint space, leading to swelling and pain [9].
  • Stiffness: Stiffness in the affected joint, making it difficult to move or perform daily activities [7].
  • Joint instability: Instability in the affected joint, which can lead to a feeling of looseness or wobbliness [9].
  • A catching, locking, or snapping sensation: A sensation where the joint catches or locks, often accompanied by pain and stiffness [9].

Other Possible Symptoms

In addition to these common symptoms, PVNS can also cause:

  • Limited range of motion: Reduced ability to move the affected joint through its normal range of motion [7].
  • Muscle weakness: Weakness in the muscles surrounding the affected joint [5].
  • Fatigue: Feeling tired or exhausted due to chronic pain and discomfort [11].

Important Note

It's essential to note that PVNS can be a diagnostic challenge, and symptoms may not always be present. If you're experiencing any of these symptoms, it's crucial to consult with a healthcare professional for proper diagnosis and treatment.

References:

[1] Context 10 [2] Context 5 [3] Context 7 [4] Context 9

Additional Symptoms

Diagnostic Tests

Diagnostic Tests for Pigmented Villonodular Synovitis (PVNS)

Pigmented villonodular synovitis (PVNS) is a rare condition that affects the joints and tendons, causing them to thicken and overgrow. Diagnosing PVNS can be challenging, but various tests can help confirm the diagnosis.

Common Diagnostic Tests for PVNS:

  • Biopsy: A biopsy involves taking a small tissue sample from the affected joint or tendon sheath. This sample is then examined under a microscope to confirm the presence of PVNS cells.
  • Magnetic Resonance Imaging (MRI): MRI scans can show characteristic changes in the synovium, such as thickening and villous formations. MRI is often used to rule out other conditions that may cause similar symptoms.
  • Computed Tomography (CT) Scan: CT scans can help identify any bone or joint abnormalities associated with PVNS.
  • X-rays: X-rays can show changes in the joint or tendon, such as thickening or erosion of the bone.
  • Physical Examination: A thorough physical examination by a healthcare professional is essential to assess the affected joint or tendon and rule out other conditions.

Other Diagnostic Tests:

  • Fine-Needle Aspiration Cytology (FNAC): FNAC involves using a fine needle to collect cells from the affected area. This test can help confirm the diagnosis of PVNS.
  • Blood Tests: Blood tests may be performed to rule out other conditions that may cause similar symptoms.

References:

  • [5] A biopsy can confirm the diagnosis of PVNS.
  • [13] The diagnosis by PVNS in the spine can be confirmed by histopathology.
  • [9] Most cases of PVNS are diagnosed using magnetic resonance imaging (MRI).
  • [10] Your doctor will perform a physical examination and use imaging studies and other tests to diagnose PVNS.

Note: These references are based on the provided context, which includes various search results related to diagnostic tests for PVNS.

Additional Diagnostic Tests

  • Blood Tests
  • Biopsy
  • Physical Examination
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT) Scan
  • X-rays
  • Fine-Needle Aspiration Cytology (FNAC)

Treatment

Drug Treatment Options for Pigmented Villonodular Synovitis (PVNS)

Pigmented villonodular synovitis (PVNS) is a rare condition that can cause painful swelling in certain joints. While surgery is often the primary treatment option, drug therapy has emerged as a viable alternative or adjunctive treatment for some patients.

Approved Drug Treatment:

  • Pexidartinib (Turalio TM): On August 2, the US Food and Drug Administration approved pexidartinib specifically to treat tenosynovial giant cell tumor (TGCT), also known as pigmented villonodular synovitis. This approval marks a significant milestone in the treatment of PVNS.
  • Imatinib: Although not specifically approved for PVNS, imatinib has been used off-label to treat certain cases of multifocal villonodular synovitis associated with Noonan syndrome.

Emerging Drug Therapies:

Researchers are actively exploring new drug treatments targeting specific proteins in the joint lining. These emerging therapies aim to provide more effective and targeted treatment options for patients with PVNS.

  • Medicines targeting a specific protein in the joint lining: Researchers are studying medicines that target this protein, which may help reduce inflammation and slow disease progression.
  • Drug therapy as an adjunctive treatment: In some cases, drug therapy may be used in conjunction with surgery to enhance treatment outcomes or manage symptoms more effectively.

Important Considerations:

When discussing drug treatment options with your doctor, it's essential to consider the following factors:

  • Effectiveness: The effectiveness of drug treatments for PVNS can vary depending on individual circumstances.
  • Side effects: As with any medication, potential side effects should be carefully weighed against the benefits of treatment.
  • Personalized approach: Your doctor will work with you to determine the best course of treatment based on your unique needs and medical history.

References:

  • [4] Pexidartinib is the first drug approved specifically to treat tenosynovial giant cell tumor (TGCT), also known as pigmented villonodular synovitis.
  • [10] Recent mechanistic understanding of the disease led to drug discovery that has opened new avenues for treatment.
  • [13] Surgical resection remains the principal treatment for nearly all localized type disease and most diffuse type, but recent advances in drug therapy have expanded treatment options.

Differential Diagnosis

Differential Diagnosis of Pigmented Villonodular Synovitis (PVNS)

Pigmented villonodular synovitis (PVNS) is a rare proliferative disease that can be challenging to diagnose due to its similarity with other joint and soft tissue disorders. The differential diagnosis of PVNS includes several conditions that may present with similar clinical features, making it essential to consider these possibilities when evaluating patients suspected of having PVNS.

Conditions to Consider:

  • Uncalcified Synovial Chondromatosis: This condition is characterized by the presence of cartilaginous nodules within the synovium, which can cause joint effusion and pain. Like PVNS, it can affect large joints such as the knee.
  • Tuberculous Arthritis: This is a rare form of tuberculosis that affects the joints, causing symptoms such as joint pain, swelling, and fever. The diagnosis of tuberculous arthritis requires a high index of suspicion and laboratory confirmation.
  • Hemophilic Arthropathy: This condition occurs in individuals with hemophilia A or B, where repeated bleeding into the joint leads to chronic inflammation and damage to the surrounding bone and soft tissues.
  • Synovial Chondromatosis: This is a rare benign tumor that affects the synovium, causing cartilaginous nodules to form within the joint. It can be difficult to distinguish from PVNS based on clinical features alone.

Key Points to Consider:

  • The differential diagnosis of PVNS requires a thorough evaluation of the patient's medical history, physical examination findings, and laboratory results.
  • Imaging studies such as MRI or CT scans may be necessary to differentiate PVNS from other conditions that affect the joints and soft tissues.
  • A multidisciplinary approach involving orthopedic surgeons, radiologists, and pathologists is often required to accurately diagnose and manage patients with suspected PVNS.

References:

[1] The major roentgen differential diagnoses of articular PVNS include uncalcified synovial chondromatosis, tuberculous arthritis, and hemophilic arthropathy. (Source: [14])

[2] Pigmented villonodular synovitis is a benign proliferative lesion of the synovium with unclear etiology. It is a locally aggressive lesion that may invade and destroy surrounding bone and soft tissues. (Source: [15])

Additional Differential Diagnoses

Additional Information

rdf-schema#domain
https://w3id.org/def/predibionto#has_symptom_9923
oboInOwl#hasOBONamespace
disease_ontology
oboInOwl#id
DOID:2702
core#notation
DOID:2702
oboInOwl#hasDbXref
UMLS_CUI:C0039106
oboInOwl#hasExactSynonym
villous tenosynovitis
rdf-schema#label
pigmented villonodular synovitis
oboInOwl#inSubset
http://purl.obolibrary.org/obo/doid#NCIthesaurus
rdf-schema#subClassOf
http://purl.obolibrary.org/obo/DOID_2703
relatedICD
http://example.org/icd10/M12.2
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class

Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.

It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.